Chikungunya - Pipeline Review, H1 2016

  • ID: 3720461
  • Drug Pipelines
  • 90 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abivax S.A.
  • Arbovax, Inc.
  • Arno Therapeutics, Inc.
  • Etubics Corporation
  • Integral Molecular, Inc.
  • Merck & Co., Inc.
  • MORE
Chikungunya - Pipeline Review, H1 2016

Summary

‘Chikungunya - Pipeline Review, H1 2016’, provides an overview of the Chikungunya pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chikungunya
- The report reviews pipeline therapeutics for Chikungunya by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chikungunya therapeutics and enlists all their major and minor projects
- The report assesses Chikungunya therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chikungunya

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chikungunya
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abivax S.A.
  • Arbovax, Inc.
  • Arno Therapeutics, Inc.
  • Etubics Corporation
  • Integral Molecular, Inc.
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Chikungunya Overview

Therapeutics Development

Pipeline Products for Chikungunya – Overview

Pipeline Products for Chikungunya – Comparative Analysis

Chikungunya – Therapeutics under Development by Companies

Chikungunya – Therapeutics under Investigation by Universities/Institutes

Chikungunya – Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Chikungunya – Products under Development by Companies

Chikungunya – Products under Investigation by Universities/Institutes

Chikungunya – Companies Involved in Therapeutics Development

Abivax S.A.

Arbovax, Inc.

Arno Therapeutics, Inc.

Bharat Biotech International Limited

Etubics Corporation

Indian Immunologicals Limited

Inovio Pharmaceuticals, Inc.

Integral Molecular, Inc.

Integrated BioTherapeutics, Inc.

Merck & Co., Inc.

Nanotherapeutics, Inc.

PaxVax, Inc.

Profectus BioSciences, Inc.

Takeda Pharmaceutical Company Limited

Themis Bioscience GmbH

Valneva SE

Chikungunya – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ABX-309 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Antibody for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AR-12 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya (viral like particles) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DEF-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMCKV-063 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MV-CHIK - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chikungunya – Recent Pipeline Updates

Chikungunya - Dormant Projects

Chikungunya – Product Development Milestones

Featured News & Press Releases

Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus

Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate

Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine

Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models

Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chikungunya, H1 2016

Number of Products under Development for Chikungunya – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Chikungunya – Pipeline by Abivax S.A., H1 2016

Chikungunya – Pipeline by Arbovax, Inc., H1 2016

Chikungunya – Pipeline by Arno Therapeutics, Inc., H1 2016

Chikungunya – Pipeline by Bharat Biotech International Limited, H1 2016

Chikungunya – Pipeline by Etubics Corporation, H1 2016

Chikungunya – Pipeline by Indian Immunologicals Limited, H1 2016

Chikungunya – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Chikungunya – Pipeline by Integral Molecular, Inc., H1 2016

Chikungunya – Pipeline by Integrated BioTherapeutics, Inc., H1 2016

Chikungunya – Pipeline by Merck & Co., Inc., H1 2016

Chikungunya – Pipeline by Nanotherapeutics, Inc., H1 2016

Chikungunya – Pipeline by PaxVax, Inc., H1 2016

Chikungunya – Pipeline by Profectus BioSciences, Inc., H1 2016

Chikungunya – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Chikungunya – Pipeline by Themis Bioscience GmbH, H1 2016

Chikungunya – Pipeline by Valneva SE, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Chikungunya Therapeutics – Recent Pipeline Updates, H1 2016

Chikungunya – Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Chikungunya, H1 2016

Number of Products under Development for Chikungunya – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Abivax S.A.
Arbovax, Inc.
Arno Therapeutics, Inc.
Bharat Biotech International Limited
Etubics Corporation
Indian Immunologicals Limited
Inovio Pharmaceuticals, Inc.
Integral Molecular, Inc.
Integrated BioTherapeutics, Inc.
Merck & Co., Inc.
Nanotherapeutics, Inc.
PaxVax, Inc.
Profectus BioSciences, Inc.
Takeda Pharmaceutical Company Limited
Themis Bioscience GmbH
Valneva SE
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll